TY - JOUR
T1 - Glaucoma and Ocular Surface Disease
T2 - More than Meets the Eye
AU - Li, Gavin
AU - Akpek, Esen Karamursel
AU - Ahmad, Sumayya
N1 - Funding Information:
Dr Esen Karamursel Akpek reports grants from National Eye Institute, Ocular Therapeutics, Novartis, W.L. Gore Inc, IRIS Registry Research Fund, Department of Defence; non-financial support from Adelphi Values, Dompe, FirstString Medical Research, HanAll, Novalique, Regeneron Healthcare Solutions, Sinqi, Xequel, Kyria, and Hawkeye, outside the submitted work. The authors report no other conflicts of interest in this work.
Publisher Copyright:
© 2022 Li et al.
PY - 2022
Y1 - 2022
N2 - Understanding the association between ocular surface disease and glaucoma is important for improving adherence to treatment and introducing practical solutions. While topical antihypertensive medications for glaucoma are well tolerated according to short-term studies, there is little evidence on their long-term effects. Since they are often required for many years, the effects of these drops on the ocular surface become important in regard to quality of life and adherence. In this nonsystematic review performed in April 2022, we summarize what is known about the relationship between glaucoma and ocular surface disease. Specifically, we examine how each class of topical glaucoma drops affects the ocular surface. We then review the treatment of ocular surface disease for patients on topical glaucoma therapy. Finally, we discuss treatments that may reduce or eliminate the burden of topical medications.
AB - Understanding the association between ocular surface disease and glaucoma is important for improving adherence to treatment and introducing practical solutions. While topical antihypertensive medications for glaucoma are well tolerated according to short-term studies, there is little evidence on their long-term effects. Since they are often required for many years, the effects of these drops on the ocular surface become important in regard to quality of life and adherence. In this nonsystematic review performed in April 2022, we summarize what is known about the relationship between glaucoma and ocular surface disease. Specifically, we examine how each class of topical glaucoma drops affects the ocular surface. We then review the treatment of ocular surface disease for patients on topical glaucoma therapy. Finally, we discuss treatments that may reduce or eliminate the burden of topical medications.
KW - adherence
KW - glaucoma
KW - ocular surface disease
UR - http://www.scopus.com/inward/record.url?scp=85141209968&partnerID=8YFLogxK
U2 - 10.2147/OPTH.S388886
DO - 10.2147/OPTH.S388886
M3 - Review article
AN - SCOPUS:85141209968
SN - 1177-5467
VL - 16
SP - 3641
EP - 3649
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
ER -